Genetic aspects of Parkinson's disease
1998; Wiley; Volume: 13; Issue: 2 Linguagem: Inglês
10.1002/mds.870130203
ISSN1531-8257
AutoresOliver Bandmann, C. D. Marsden, Nicholas Wood,
Tópico(s)Neurological diseases and metabolism
ResumoMovement DisordersVolume 13, Issue 2 p. 203-211 Review Genetic aspects of Parkinson's disease Oliver Bandmann MD, Oliver Bandmann MD University Department of Clinical Neurology, Institute of Neurology, Queen Square, London, UKSearch for more papers by this authorC. David Marsden FRS, C. David Marsden FRS University Department of Clinical Neurology, Institute of Neurology, Queen Square, London, UKSearch for more papers by this authorDr. Nicholas W. Wood MD, Corresponding Author Dr. Nicholas W. Wood MD University Department of Clinical Neurology, Institute of Neurology, Queen Square, London, UKUniversity Department of Clinical Neurology, Institute of Neurology, Queen Square, London, WC1N 3BG, UKSearch for more papers by this author Oliver Bandmann MD, Oliver Bandmann MD University Department of Clinical Neurology, Institute of Neurology, Queen Square, London, UKSearch for more papers by this authorC. David Marsden FRS, C. David Marsden FRS University Department of Clinical Neurology, Institute of Neurology, Queen Square, London, UKSearch for more papers by this authorDr. Nicholas W. Wood MD, Corresponding Author Dr. Nicholas W. Wood MD University Department of Clinical Neurology, Institute of Neurology, Queen Square, London, UKUniversity Department of Clinical Neurology, Institute of Neurology, Queen Square, London, WC1N 3BG, UKSearch for more papers by this author First published: 04 November 2004 https://doi.org/10.1002/mds.870130203Citations: 24AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Nasir J, Goldberg Y, Hayden M. Huntington disease: new in sights into the relationship between CAG expansion and disease. Hum Mol Genet 1996; 5: 1431–1435. 2 Gowers W. A manual of diseases of the nervous system. London: J & A Churchill, 1888: 589f. 3 Kückens H. Über Heredofamiliarität bei Paralysis agitans. Klin Wochenschr 1925; 4: 2289–2291. 4 Mjönes H. Paralysis agitans. A clinical genetic study. Acta Neurol Scand 1949; 25(suppl 54): 1–195. 5 Duvosin R. The genetics of Parkinson's disease. Adv Neurol 1993; 60: 306–315. 6 Payami H, Larsen K, Bernard S, Nutt J. Increased risk of Parkinson's disease in parents and siblings of patients. Ann Neurol 1994; 36: 659–661. 7 Seidler A, Hellenbrand W, Robra B-P, et al. Possible environmental, occupational and other etiologic factors for Parkinson's disease: a case control study in Germany. Neurology 1996; 46: 1275–1284. 8 De Michele G, Filla A, Volpe G, et al. Environmental and genetic risk factors in Parkinson's disease: a case-control study in southern Italy. Mov Disord 1996; 11: 17–23. 9 Semchuk K, Love E, Lee R. Parkinson's disease: a test of the multifactorial etiologic hypothesis. Neurology 1993; 43: 1173–1180. 10 Marder K, Tang M-X, Mejia H, et al. Risk of Parkinson's disease among first degree relatives: a community based study. Neurology 1996; 47: 155–160. 11 Fleming L, Mann J, Bean J, Briggle T, Sanchez-Ramos J. Parkinson's disease and brain levels of organochlorine pesticides. Ann Neurol 1994; 36: 100–103. 12 Martyn C, Osmond C. Parkinson's disease and the environment in early life. J Neurol Sci 1995; 132: 201–206. 13 Quinn N, Critchley P, Marsden CD. Young onset Parkinson's disease. Mov Disord 1987; 2: 73–91. 14 Takahashi H, Ohama E, Suzuki S, et al. Familial juvenile parkinsonism: clinical and pathologic study in a family. Neurology 1994; 44: 437–441. 15 Vogel F, Motulski A. Population genetics. In: F Vogel, A Motulski, eds. Human genetics: problems and approaches. Berlin: Springer, 1986: 205–218. 16 Marsden CD. Parkinson's disease in twins. J Neurol Neurosurg Psychiatry 1987; 50: 105–106. 17 Martilla R, Kaprio J, Kostenvuo M, Rinne U. Parkinson's disease in a nationwide twin cohort. Neurology 1988; 38: 1217–1219. 18 Ward C, Duvoisin R, Ince S, Nutt J, Eldridge R, Calne D. Parkinson's disease in 65 pairs of twins and in a set of quadruplets. Neurology 1983; 33: 815–824. 19 Johnson W, Hodge S, Duvoisin R. Twin studies and the genetics of Parkinson's disease–a reappraisal. Mov Disord 1990; 5: 187–194. 20 Vieregge P, Schiffke K, Friedrich H, Müller B, Ludin H. Parkinson's disease in twins. Neurology 1992; 42: 1453–1461. 21 Gibb W, Lees A. The relevance of the Lewy body in the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988; 51: 745–752. 22 Burn D, Mark M, Playford E, et al. Parkinson's disease in twins studied with 18F-dopa and positron emission tomography. Neurology 1992; 42: 1894–1900. 23 Holthoff V, Vieregge P, Kessler J, et al. Discordant twins with Parkinson's disease: positron emission tomography and early signs of impaired cognitive circuits. Ann Neurol 1994; 36: 176–182. 24 Hughes A, Daniel S, Kilford L, Lees A. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study. J Neurol Neurosurg Psychiatry 1992; 55: 181–184. 25 Bell J, Clark A. A pedigree of paralysis agitans. Annals of Eugenics 1926; I: 455–462. 26 Golbe L, Lazzarini A, Schwarz K, Mark M, Dickson D, Duvoisin R. Autosomal dominatnt parkinsonism with benign course and typical Lewy-body pathology. Neurology 1993; 43: 2222–2227. 27 Golbe L, Di Iorio G, Sanges G, et al. Clinical genetic analysis of Parkinson's disease in the Contursi Kindred. Ann Neurol 1996; 40: 767–775. 28 Polymeropoulos M, Higgins J, Golbe L, et al. Mapping of a gene for Parkinson's disease to chromosome 4q21-23. Science 1996; 274: 1197–1199. 29 Gasser T, Muller-Myhsok B, Wszolek ZK, et al. Genetic heterogeneity in familial parkinsonism: no linkage to the PD-1 locus on chromosome 4q in 11 of 13 families. Science 1997; 277: 388–389. 30 Levy-Lahad E, Bird T. Genetic factors in Alzheimer's disease: a review of recent advances. Ann Neurol 1996; 40: 829–840. 31 Siddique T, Deng H-X. Genetics of amyotrophic lateral sclerosis. Hum Mol Genet 1996; 5: 1465–1470. 32 Wszolek Z, Pfeiffer B, Fulgham J, et al. Western Nebraska family (family D) with autosomal dominant parkinsonism. Neurology 1995; 45: 502–505. 33 Waters C, Miller C. Autosomal dominant Lewy body parkinsonism in a four-generation family. Ann Neurol 1994; 35: 59–64. 34 Degl'Innocenti F, Maurello M, Marini P. A parkinsonian kindred. Ital J Neurol Sci 1989; 10: 307–310. 35 Markopoulou K, Wszolek ZK, Pfeiffer RF. A Greek-American kindred with autosomal dominant, levodopa-responsive parkinsonism and anticipation. Ann Neurol 1995; 38: 373–378. 36 Piccini P, Morrish PK, Turjanski N, et al. Dopaminergic function in familial Parkinson's disease: a clinical and 18F-dopa study. Ann Neurol 1997; 41: 222–229. 37 Sawle GV, Wroe SJ, Lees AJ, et al. The identification of presymptomatic parkinsonism: clinical and 18F-dopa positron emission tomography studies in an Irish kindred. Ann Neurol 1992; 32: 609–617. 38 Willems P. Dynamic mutations hit double figures. Nat Genet 1994; 8: 221–228. 39 Payami H, Bernard S, Larsen K, Kaye J, Nutt J. Genetic anticipation in Parkinson's disease. Neurology 1995; 45: 135–138. 40 Maraganore D, Schaid D, Rocca W, Harding AE. Anticipation in familial Parkinson's disease: a reanalysis of 13 United Kingdom kindreds. Neurology 1996; 47: 1512–1517. 41 Wszolek ZK, Cordes M, Calne DB, Münter MD, Cordes I, Pfeifer RF. Hereditärer Morbus Parkinson: Bericht über drei Familien mit autosomal-dominantem Erbgang. Nervenarzt 1993; 64: 331–335. 42 Carrero-Valenzuela R, Lindblad K, Payami H, et al. No evidence for association of familial Parkinson's disease with CAG repeat expansion. Neurology 1995; 45: 1760–1763. 43 Gasser T, Wszolek Z, Trofatter J, et al. Genetic linkage studies in autosomal dominant parkinsonism: evaluation of seven candidate genes. Ann Neurol 1994; 36: 387–396. 44 Supala A, Wszolek Z, Trofatter J, et al. Genetic linkage studies in autosomal dominant parkinsonism: evaluation of candidate genes. Mov Disord 1994; 9: 32. 45 Plante-Bordeneuve P, Davis M, Maraganore D, Marsden CD, Harding AE. Debrisoquine hydroxylase gene polymorphism in familial Parkinson's disease. J Neurol Neurosurg Psychiatry 1994; 57: 911–913. 46 Plante-Bordeneuve V, Davis M, Maraganore D, Marsden C, Harding A. Tyrosine hydroxylase gene polymorphism in familial and sporadic Parkinson's disease. Mov Disord 1994; 9: 337–339. 47 Rosen D, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993; 362: 59–62. 48 Burrow J, Blumbergs P. Substantia nigra degeneration in motor neuron disease: a quantitative study. Aust NZ J Med 1992; 22: 469–472. 49 Takahashi H, Snow B, Bhatt M, Peppard R, Eisen A, Calne D. Evidence for a dopaminergic deficit in sporadic amyotrophic lateral sclerosis on positron emission scanning. Lancet 1993; 342: 1016–1018. 50 Majoor-Krakauer D, Ottman R, Johnson W, Rowland L. Familial aggregation of amyotrophic lateral sclerosis, dementia, and Parkinson's disease: evidence of shared genetic susceptibility. Neurology 1994; 44: 1872–1877. 51 Przedborski S, Kostic V, Jackson-Lewis V, et al. Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. J Neurosci 1992; 12: 1658–1667. 52 Bandmann O, Davis M, Marsden CD, Harding AE. Sequence of the superoxide dismutase 1 (SOD1) gene in familial Parkinson's disease. J Neurol Neurosurg Psychiatry 1995; 59: 90–91. 53 Parboosingh J, Rousseau M, Rogan F, et al. Absence of mutations in superoxide dismutase and catalase genes in patients with Parkinson's disease. Arch Neurol 1995; 52: 1160–1163. 54 Tuite P, Rogaeva E, St George-Hyslop PH, et al. Dopa-responsive parkinsonism phenotype of Machado-Joseph disease: confirmation of 14q CAG expansion. Ann Neurol 1995; 38: 684–687. 55 Dexter D, Sian J, Rose S, et al. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann Neurol 1994; 35: 38–44. 56 Barbeau A, Cloutier T, Roy M, Plasse L, Paris S, Poirier J. Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine. Lancet 1985; 1213–1215. 57 Benitez J, Ladero J, Jimenez F, et al. Oxidative polymorphism of debrisoquine in Parkinson's disease. J Neurol Neurosurg Psychiatry 1990; 53: 289–292. 58 Kallio J, Marttila R, Rinne U, Sonninen V, Syvälahti E. Debrisoquine oxidation in Parkinson's disease. Acta Neurol Scand 1991; 83: 194–197. 59 Steiger M, Lledo P, Quinn N, Marsden D, Turner P, Jenner P. Debrisoquine hydroxylation in Parkinson's disease. Acta Neurol Scand 1992; 86: 159–164. 60 Armstrong M, Daly A, Cholerton S, Bateman D, Idle J, Mutant debrisoquine hydroxylation genes in Parkinson's disease. Lancet 1992; 339: 1017–1018. 61 Smith C, Gough A, Leigh P, et al. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet 1992; 339: 1375–1377. 62 Kurth M, Kurth J. Variant cytochrome P450 CYP2D6 allelic frequencies in Parkinson's disease. Am J Med Genet 1993; 48: 166–168. 63 Agundez J, Jimenez-Jimenez F, Luengo A, et al. Association between the oxidative polymorphism and early onset of Parkinson's disease. Clin Pharmacol Ther 1995; 57: 291–298. 64 Gasser T, Müller-Myhsok B, Supala A, et al. The CYP2D6B allele is not overrepresented in a population of German patients with idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1996; 61: 518–520. 65 Diederich N, Hilger C, Goetz C, Vieregge P, Metz H. Genetic variability of the CYP2D6 gene is not a risk factor for sporadic Parkinson's disease. Ann Neurol 1996; 40: 463–465. 66 Sandy M, Armstrong M, Tanner C, et al. CYP2D6 allelic frequencies in young-onset Parkinson's disease. Neurology 1996; 47: 225–230. 67 Ibarreta D, Gomez-Isla T, Portera-Sanchez A, Parrilla R, Ayuso M. Apolipoprotein E genotype in Spanish patients of Alzheimer's or Parkinson's disease. J Neurol Sci 1995; 134: 146–149. 68 Koller W, Glatt S, Hubble J, et al. Apolipoprotein E genotypes in Parkinson's disease with and without dementia. Ann Neurol 1995; 37: 242–245. 69 Whitehead A, Bertrandy S, Finnan F, Butler A, Smith G, Ben-Shlomo Y. Frequency of the apolipoprotein E e4 allele in a casecontrol study of early onset Parkinson's disease. J Neurol Neurosurg Psychiatry 1996; 61: 347–351. 70 Riederer P, Konradi C, Hebenstreit G, Youdim M. Neurochemical perspectives to the function of monoamine oxidase. Acta Neurol Scand 1989; 126: 41–45. 71 Langston J, Irwin I, Tetrud J, Langston E, Forno E. Pargyline prevents MPTP induced parkinsonism in primates. Science 1984; 225: 1480–1482. 72 Kurth J, Kurth M, Poduslo S, Schwankhaus J. Association of a monoamine oxidase B allele with Parkinson's disease. Ann Neurol 1993; 33: 368–372. 73 Ho S, Kapadi A, Ramsden D, Williams A. An allelic association study of monoamine oxidase B in Parkinson's disease. Ann Neurol 1995; 37: 403–405. 74 Hotamisligil G, Girmen A, Fink J, et al. Hereditary variations in monoamine oxidase as a risk factor for Parkinson's disease. Mov Disord 1994; 9: 305–310. 75 Higuchi S, Muramatsu T, Arai H, Hayashida M, Sasaki H, Trojanowski J. Polymorphisms of dopamine receptor and transporter genes and Parkinson's disease. J Neural Transm 1995; 10: 107–113. 76 Baker H, Joh T, Reis D. Genetic control of number of midbrain dopaminergic neurosns in inbred strains of mice: relationship to size and neuronal density of the striatum. Proc Natl Acad Sci USA 1980; 77: 4369–4373. 77 Gaspar P, Ben Jelloun N, Febvret A. Sparing of the dopaminergic neurons containing calbindin-D28k and of the dopaminergic mesocortical projections in weaver mutant mouse. Neuroscience 1994; 61: 293–305. 78 Gupta M, Felten D, Ghetti B. Selective loss of monoaminergic neurons in weaver mutant mice–an immunocytochemical study. Brain Res 1987; 402: 379–382. 79 Schmidt M, Sawyer B, Perry K, Fuller R, Foreman M, Ghetti B. Dopamine deficiency in the weaver mutant mouse. J Neurosci 1982; 2: 376–380. 80 Verney C, Febvret-Muzerelle A, Gaspar P. Early postnatal changes of the dopaminergic mesencephalic neurons in the weaver mouse. Brain Res Dev Brain Res 1995; 89: 115–119. 81 Patil N, Cox D, Bhat D, Faham M, Myers R, Peterson A. A potassium channel mutation in weaver mice implicates membrane excitability in granule cell differentiation. Nat Genet 1995; 11: 126–129. 82 Bandmann O, Davis M, Marsden CD, Wood NW. The human homologue of the weaver mouse gene in familial and sporadic Parkinson's disease. Neuroscience 1996; 72: 877–879. 83 Mochizuki H, Goto K, Mori H, Mizuno Y. Histochemical detection of apoptosis in Parkinson's disease. J Neurol Sci 1996; 137: 120–123. 84 Hochman A, Offen D, Sternin H, Korsmeyer S, Ziv I, Melamed E. Neurons from bcl-2-deficient mice are more susceptible to dopamine-induced oxidative stress. Mov Disord 1996; 11: 592–593. 85 Trimmer P, Smith T, Jung A, Bennett J. Dopamine neurons from transgenic mice with a knockout of the p53 gene resist MPTP neurotoxicity. Neurodegeneration 1996; 5: 233–239. 86 Bennecke R, Struemper P, Wiess H. Electron transfer complexes I and IV of platelets are abnormal in Parkinson's disease but normal in Parkinson-plus syndromes. Brain 1993; 116: 1451–1463. 87 Haas R, Nasirian F, Nakano K, et al. Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease. Ann Neurol 1995; 37: 714–722. 88 Schapira A, Cooper J, Dexter D, Jenner P, Clark J, Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease [Letter]. Lancet 1989; I: 1269. 89 Swerdlow R, Parks J, Miller S, et al. Origin and functional consequences of the complex I defect in Parkinson's disease. Ann Neurol 1996; 40: 663–671. 90 Lestienne P, Nelson I, Riederer P, Jellinger K, Reichmann H. Normal mitochondrial genome in brain from patients with Parkinson's disease and complex I defects. J Neurochem 1990; 55: 1810–1812. 91 Mann VM, Cooper JM, Schapira AHV. Quantitation of a mitochondrial DNA deletion in Parkinson's disease. FEBS Lett 1992; 299: 218–222. 92 Sandy MS, Langston JM, Smith MT, DiMonte DA. PCR analysis of platelet mtDNA: lack of specific changes in Parkinson's disease. Mov Disord 1993; 8: 74–82. 93 Kösel S, Lücking CB, Egensberger R, Mehraein P, Graeber MB. Mitochondrial NADH dehydrogenase and CYP2D6 genotypes in Lewy-body parkinsonism. J Neurosci Res 1996; 44: 174–183. 94 Shoffner J, Brown M, Torroni A, et al. Mitochondrial DNA variants observed in Alzheimer disease and Parkinson disease patients. Genomics 1993; 17: 171–184. 95 Schapira A, Holt I, Sweeney M, Harding AE, Jenner P, Marsden CD. Mitochondrial DNA analysis in Parkinson's disease. Mov Disord 1990; 5: 294–297. 96 Bandmann O, Sweeney M, Daniel S, Marsden CD, Wood NW. Mitochondrial DNA polymorphisms in pathologically proven Parkinson's disease. J Neurol 1997; 244: 262–265. 97 Maraganore D, Harding AE, Marsden CD. A clinical and genetic study of familial Parkinson's disease. Mov Disord 1991; 6: 205–211. 98 Zweig R, Singh A, Cardillo J, Langston J. The familial occurrence of Parkinson's disease. Arch Neurol 1992; 49: 1205–1207. 99 Wooten G, Currie L, Bennett J, Harrison M, Trugman J, Parker W. Maternal inheritance of Parkinson's disease. Ann Neurol 1997; 41: 265–268. 100 Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 1997; 276: 2045–2047. Citing Literature Volume13, Issue2March 1998Pages 203-211 ReferencesRelatedInformation
Referência(s)